Date: March 28, 2022
To: Health Care Providers and Health Care Facilities
From: New York State Department of Health

**UPDATE ON SOTROVIMAB TREATMENT RECOMMENDATIONS**

On March 25, 2022, the [FDA updated the Emergency Use Authorization (EUA)](https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs) fact sheet for the COVID-19 monoclonal antibody treatment sotrovimab. Due to the prevalence of Omicron sub-variants such as BA.2, sotrovimab is not currently authorized for treatment in New York.

According to the most recent [CDC projections](https://www.cdc.gov/coronavirus/2019-ncov/patient/who-is-at-risk.html), Omicron and its variants are estimated to account for 99% of new COVID-19 cases in HHS Region 2 (which includes New York, New Jersey, Puerto Rico, and US Virgin Islands). Per the [health care provider fact sheet](https://www.cdc.gov/coronavirus/2019-ncov/patient/who-is-at-risk.html), data has shown that sotrovimab is unlikely to be effective against the BA.2 sub-variant. As a result, the FDA has suspended the authorization for sotrovimab treatment in HHS Regions 1 and 2.

Providers that have sotrovimab on-hand should cease its use but maintain remaining supplies under proper storage conditions so that they may be used if authorization is given again in the future.

Providers are encouraged to follow prescribing guidelines for COVID-19 treatment and consider all treatment options. There are several other therapies – Paxlovid, Veklury (remdesivir), bebtelovimab, and Lagevrio (molnupiravir) – that are expected to be effective against the BA.2 sub-variant, and that are authorized or approved to treat certain patients with COVID-19. The [therapeutic locator tool](https://www.medicationslocator.org/) can be used to see the amount of available therapeutic in a region.

For information on monoclonal antibodies please refer to NYSDOH’s [COVID-19 Monoclonal Antibody (mAb) Therapeutics Information for Providers](https://www.health.ny.gov/disease/coronavirus/covid-19/antibodies).